Episodes

  • The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

    The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations
    Oct 2 2024
    Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.
    Show more Show less
    58 mins
  • Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors

    Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors
    Sep 19 2024
    Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
    Show more Show less
    59 mins
  • Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

    Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation
    Sep 12 2024
    Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.
    Show more Show less
    2 hrs and 3 mins
  • Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

    Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer
    Aug 21 2024
    Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.
    Show more Show less
    1 hr and 1 min
  • Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer

    Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer
    Aug 14 2024
    Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer.
    Show more Show less
    1 hr and 2 mins
  • Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
    Aug 5 2024
    Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.
    Show more Show less
    1 hr and 1 min
  • Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation

    Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation
    Jul 25 2024
    Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.
    Show more Show less
    48 mins
  • Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
    Jun 12 2024
    Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.
    Show more Show less
    1 hr and 1 min